420 subjects ÷ 42 months (3.5 years) = 10 subjects/month .

However, “expected average” often rounds up to next whole number, ensuring enrollment goals are met. Thus, 11/month is correct.

This calculation is important for feasibility assessments and protocol planning.

The regulatory binder (investigator site file) must contain documents verifying qualifications of all personnel. These include curricula vitae (CVs), professional licenses, and training certificates.

ICH E6(R2) 4.1.5: “The investigator should ensure that all persons assisting with the trial are qualified by education, training, and experience… Current curriculum vitae and/or other relevant documents evidencing qualifications should be maintained.”

21 CFR 312.53(c)(1): Sponsors must select investigators qualified “by training and experience,” and investigators must provide sufficient documentation, typically updated CVs.

Letters of promotion (A), training brochures (B), or performance reviews (C) may remain in personnel files but are not required regulatory documents. The only acceptable regulatory proof is an updated CV (D), which reflects the individual’s training and qualifications for their new role.

Therefore, the correct answer is D (Updated CV). This ensures compliance with ICH and FDA requirements for staff qualification documentation in clinical research.

21 CFR 11.100(a): Requires that electronic signatures be “unique to one individual and shall not be reused or reassigned to anyone else.”

This ensures accountability and audit trail integrity.

Form FDA 1572 is the investigator’s signed agreement to follow regulations.

21 CFR 312.53(c)(1)(vi)(c): Requires investigators to sign Form 1572, committing to conduct trials in accordance with FDA regulations (21 CFR 50 & 56) .

The form includes commitments to personally supervise, obtain informed consent, maintain records, and permit FDA inspections.

It does not include financial disclosures (covered under 21 CFR 54 ) or preclinical data (in the IB ).

21 CFR 812.150(a)(4): Any deviation from investigational plan made to protect the life or physical well-being of a subject in an emergency must be reported to the sponsor and IRB within 5 working days .

Unanticipated adverse device effects have a 10-day reporting window.

ICH E6(R2) 5.5.3(g): Requires audit trails for any data changes, recording date, time, and person responsible. This ensures traceability and regulatory compliance.

Other restrictions (B–D) are not mandated under ICH.

Monitoring reports are sponsor-controlled documents.

ICH E6(R2) 5.18.6: “The monitor should submit a written report to the sponsor after each trial-site visit… The sponsor should review and follow up on the monitoring report.”

ICH E6(R2) 8.1 & 8.2.22: Monitoring visit reports are essential documents maintained by the sponsor.

Investigators are not required to retain monitoring reports; they maintain site regulatory binders and subject records. The study coordinator assists investigators, but does not hold sponsor-owned reports. IRBs also do not receive sponsor monitoring reports.

Thus, the correct answer is B (The sponsor).

Handling of investigational product (IP), including returns, is governed by sponsor’s written procedures .

ICH E6(R2) 4.6.3: “The investigator/institution should maintain records of the product’s delivery, the inventory, the use by each subject, and the return to the sponsor or alternative disposition.”

ICH E6(R2) 5.13.3: “The sponsor should ensure that written procedures include instructions for… the return or alternative disposition of unused product(s).”

The IB (A) describes pharmacology and safety, not IP logistics. CRO agreements (C) cover contractual duties, not product return processes. Local pharmacy policies (D) may apply operationally but do not override sponsor-required procedures.

Thus, the correct answer is B (The sponsor’s written procedures).

ICH E6(R2) 4.5.1: “The investigator should conduct the trial in compliance with the protocol approved by IRB/IEC.”

Deviations must not occur unless to eliminate hazard. Eligibility criteria cannot be overridden by investigator opinion.

Thus, enrollment requires protocol amendment and IRB approval.

The protocol signature page documents agreement between the sponsor and the investigator/institution to conduct the trial in compliance with ICH GCP, the protocol, and regulatory standards.

ICH E6(R2) 8.2.2 (Signed protocol and amendments): Requires “the sponsor and investigator/institution to sign the protocol and amendments, confirming agreement.”

ICH E6(R2) 4.5.1: “The investigator should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, approved by the regulatory authority(ies) and by the IRB/IEC.”

The sponsor–investigator signatures ensure shared accountability for subject protection, data integrity, and adherence to trial methodology. Neither delegated staff (B) nor IRB/IEC (C) nor FDA (D) sign protocols. These bodies approve or oversee, but do not formally enter into execution of the protocol.

Thus, the correct answer is A (The investigator/institution and the sponsor) .